Remove roche-touts-lunsumios-durable-efficacy-abbvie-regeneron-plot-lymphoma-bispecific-battle
article thumbnail

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

Fierce Pharma

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle. Sat, 12/10/2022 - 22:30.

205
205